Securities code: Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) securities abbreviation: Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) Announcement No.: 2022017
Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403)
Announcement on more than half of the implementation time of the share reduction plan of shareholders holding more than 5%
Shenzhen shipping Health Technology Co., Ltd., a shareholder holding more than 5%, guarantees that the information provided to the company will be included
The contents are true, accurate and complete, without false records, misleading statements or major omissions.
The company and all members of the board of directors guarantee that the contents of the announcement are consistent with the information provided by the information disclosure obligor.
Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) (hereinafter referred to as “the company”, Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) ) Shareholding
More than 5% of the shareholders of Shenzhen shipping Health Technology Co., Ltd. (hereinafter referred to as “shipping health”) are due to their own
It is proposed to reduce all shares of the company by means of centralized bidding transaction, block transaction and agreement transfer
For details, please refer to the securities times on May 13, 2021 and November 12, 2021
And cninfo (www.cn. Info. Com. CN.) Disclosed Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403)
Announcement on pre disclosure of share reduction plan of shareholders holding more than 5% (Announcement No.: 2021055
2021097）。
The company received the notification letter on more than half of the implementation time of the share reduction plan issued by shipping health
By March 3, 2022, the implementation time of the aforementioned reduction plan of shipping health has been more than half. According to the China Securities Regulatory Commission
Several provisions on the reduction of shares held by shareholders, directors, supervisors and senior executives of listed companies and shareholders of Listed Companies in Shenzhen Stock Exchange
And the detailed rules for the implementation of share reduction by directors, supervisors and senior managers
The report is as follows:
1、 Shareholder reduction
1. Share reduction by shareholders
Shareholder name reduction method reduction time reduction average price (yuan / share) reduction number of shares (share) reduction proportion%
Block trading from December 3, 2021 to January 25, 202226.171465 Shenzhen Cereals Holdings Co.Ltd(000019) 9885%
Shipping health
Centralized bidding from December 3, 2021 to January 20, 202227.287325397099948%
Total — 21975397299833%
2. Shareholding of shareholders before and after reduction
Shareholder name share nature shares held before this reduction shares held after this reduction
Number of shares (shares) in total share capital% number of shares (shares) in total share capital%
Total shares held: 617172018.42% 397418045.422%
Shipping health, including: 61717201 tradable shares with unlimited sales conditions 8.42% 397418045.422%
Tradable shares with limited sales conditions 0%
2、 Description of other matters
1. On February 9, 2022, Shenzhen Stock Exchange issued the “on health technology of Shenzhen shipping”
The decision of the company to issue a notice of criticism (SZS [2022] No. 137) was approved by Shenzhen Securities Exchange
It was found that there were the following violations in shipping health: “from June 28, 2021 to September 17, 2021
During the period, as a shareholder of Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) holding more than 5%, shipping health reduced its holdings through centralized bidding
Lin Jinyu Bio-Technology Co.Ltd(600201) 8083100 shares, with a reduction ratio of 110308%. Within any 90 consecutive natural days,
The total number of shares reduced by shipping health exceeds 1% of the total number of Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) shares. ” Shipping health above line
In order to violate articles 1.4 and 3.1.8 of the stock listing rules (revised in 2020) of Shenzhen Stock Exchange
Article and Shenzhen Stock Exchange’s implementation of share reduction by shareholders, directors, supervisors and senior managers of listed companies
Article 4 of the rules. In view of the above violation facts and circumstances, according to the stock exchange of Shenzhen Stock Exchange
Article 16.2 of the municipal rules (revised in 2020) and the implementation standard of disciplinary measures for listed companies (Trial)
The provisions of Article 33 shall be examined and approved by the Disciplinary Committee of Shenzhen Stock Exchange and Shenzhen Stock Exchange
The following punishment decisions were made: a notice of criticism shall be given to the shipping health.
On the same day, it issued a letter of reply to Cao Sheng, Zhou Yawen, Zhou Hanfu, Yin bin, Yan Lin, Chen Hao and Shao Yinfei
The decision to circulate a notice of criticism (SZS [2022] No. 138) was found out by Shenzhen Stock Exchange and Cao
Sheng, Zhou Yawen, Zhou Hanfu, Yin bin, Yan Lin, Chen Hao and Shao Yinfei have the following violations: “2021
From August 23 to October 15, 2003, Cao Sheng, Zhou Yawen, Zhou Hanfu, Yin bin, Yan Lin, Chen Hao
Shao Yinfei transferred the shares held by the shareholders of Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) holding more than 5% of the shares through block trading
Before the initial public offering of linbio, there were 1770900 shares, 1200000 shares, 4095600 shares and 2800000 shares
Shares, 1580000 shares, 800000 shares, 1 Shanghai Pudong Development Bank Co.Ltd(600000) shares, and from August 24 to October 2021
The reduction of the above-mentioned transferred shares was completed during the 19th.
Cao Sheng, Zhou Yawen, Zhou Hanfu, Yin bin, Yan Lin, Chen
Hao and Shao Yinfei illegally reduced their holdings of Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) shares within six months after they received Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) shares through block trading
Behavior. ” Cao Sheng, Zhou Yawen, Zhou Hanfu, Yin bin, Yan Lin, Chen Hao and Shao Yinfei violated the above-mentioned acts
Articles 1.4 and 3.1.8 of the stock listing rules (revised in 2020) of Shenzhen Stock Exchange and
Article 5 of the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of municipal companies. Learn from
The above violation facts and circumstances shall be in accordance with the stock listing rules (revised in 2020) of Shenzhen Stock Exchange
Article 16.2 and Article 35 of the standards for the implementation of disciplinary measures of listed companies (for Trial Implementation), after deliberation and approval by the Disciplinary Committee of Shenzhen Stock Exchange, Shenzhen Stock Exchange made the following disciplinary decisions: Cao Sheng, Zhou Yawen, Zhou Hanfu, Yin bin, Yan Lin, Chen Hao and Shao Yinfei were given the punishment of circulating a notice of criticism.
2. The implementation of this share reduction is consistent with the shipping health reduction plan disclosed by the company on November 12, 2021.
3. Shipping health is not the controlling shareholder or actual controller of the company. This share reduction will not lead to changes in the controlling shareholder and actual controller of the company, and will not have an impact on the corporate governance structure and sustainable operation. 4. As of the disclosure date of the announcement, the implementation of the reduction plan of shipping health shares has not been completed. The company will continue to pay attention to the progress and fulfill the obligation of information disclosure in time in accordance with relevant regulations.
3、 Documents for future reference.
1. Notification letter on more than half of the implementation time of share reduction plan issued by shipping health
It is hereby announced.
Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) board of directors
March 5, 2002
